Ma Bin, Wang Jiajun, Song Yongxi, Gao Peng, Sun Jingxu, Chen Xiaowan, Yang Yuchong, Wang Zhenning
Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, People's Republic of China.
Onco Targets Ther. 2016 Jan 21;9:445-53. doi: 10.2147/OTT.S98613. eCollection 2016.
Long noncoding RNAs (lncRNAs) with dysregulated expression levels have been investigated in numerous types of different cancer. Whether lncRNAs can predict the progression of gastric cancer (GC) still remains largely unclear. The aim of our study was to investigate whether KRT18P55, a novel intergenic lncRNA, can be a predictive biomarker for GC.
To determine the expression levels of KRT18P55 in GC, we evaluated it in five GC cell lines (SGC-7901, MGC-803, BGC-823, AGS, and HG27) and 97 GC tissue samples in comparison with a normal control by quantitative polymerase chain reaction. In addition, the association with patient clinicopathological characteristics was analyzed to identify the clinical significance of KRT18P55. We also used publicly accessible data from The Cancer Genome Atlas (TCGA) to further verify the expression levels and clinical significance of KRT18P55. Furthermore, a receiver operating characteristic curve was also conducted to evaluate the diagnostic value of KRT18P55 for GC.
A significant upregulation was observed in GC cell lines (P<0.01) and tissue samples (P<0.01). This finding was consistent with the results of 29 pairs of GC tissue samples from TCGA (P<0.01). Additionally, we indicated that the increased expression of KRT18P55 was related to the progression of intestinal type (P=0.032), which was also supported by results of independent GC cohorts from TCGA (P<0.01). However, we did not find significant difference in prognosis between patients with high and low expression of KRT18P55 (P>0.05). Finally, KRT18P55 showed potential diagnostic value for GC with an area under the receiver operating characteristic curve of 0.733 (P<0.01).
Upregulated KRT18P55 was a novel biomarker for the progression of GC, especially for the intestinal type.
长链非编码RNA（lncRNA）表达水平失调已在多种不同类型癌症中得到研究。lncRNA是否能预测胃癌（GC）进展在很大程度上仍不清楚。我们研究的目的是调查新型基因间lncRNA KRT18P55是否可作为GC的预测生物标志物。
为确定KRT18P55在GC中的表达水平，我们通过定量聚合酶链反应，将其在5种GC细胞系（SGC-7901、MGC-803、BGC-823、AGS和HG27）及97份GC组织样本中与正常对照进行比较评估。此外，分析其与患者临床病理特征的关联以确定KRT18P55的临床意义。我们还使用来自癌症基因组图谱（TCGA）的公开数据进一步验证KRT18P55的表达水平及临床意义。此外，还绘制了受试者工作特征曲线以评估KRT18P55对GC的诊断价值。
在GC细胞系（P<0.01）和组织样本（P<0.01）中观察到显著上调。这一发现与来自TCGA的29对GC组织样本结果一致（P<0.01）。此外，我们表明KRT18P55表达增加与肠型进展相关（P=0.032），这也得到了来自TCGA的独立GC队列结果的支持（P<0.01）。然而，我们未发现KRT18P55高表达和低表达患者在预后方面存在显著差异（P>0.05）。最后，KRT18P55对GC显示出潜在诊断价值，受试者工作特征曲线下面积为0.733（P<0.01）。
KRT18P55上调是GC进展的新型生物标志物，尤其是对肠型而言。
